Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Knee surgery patients get bone marrow shot to halt arthritis

NCT ID NCT02582489

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether injecting a concentrated sample of a patient's own bone marrow into the knee right after meniscus surgery can slow down or prevent arthritis. One hundred adults with a torn meniscus will receive either the bone marrow injection or a saltwater placebo, and their knee function, pain, and imaging results will be tracked for a year. The goal is to see if this simple procedure can improve long-term outcomes after a common knee operation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bone marrow aspirate concentrate (BMAC)
What this could lead to
If it works, this could point toward a way to slow or prevent osteoarthritis after knee surgery, potentially reducing pain and improving long-term knee function.
What could go wrong
This is a small, early-phase trial with only 100 participants. The treatment may not provide any benefit over a placebo, and the effects on osteoarthritis progression are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2017

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject is greater than 18 years old * Written informed consent is obtained * Subject is determined to have a symptomatic meniscal tear requiring a meniscectomy * Meniscal pathology is confirmed through MRI and arthroscopically * Subject agrees to all follow-up evaluations * Osteoarthritis Kellen-Lawrence grade 1-3 on flexion PA and extension AP views Exclusion Criteria: * Any subject lacking decisional capability * Unwillingness to participate in the necessary follow-up * Subject is pregnant or may become pregnant * History of diabetes mellitus * History of rheumatoid arthritis or other autoimmune disorder * History of solid organ or hematologic transplantation * Diagnosis of a non-basal cell malignancy within the preceding 5 years * Infection requiring antibiotic treatment within the preceding 3 months * Osteoarthritis Kellen-Lawrence grade 4 on flexion posterior-anterior (PA) or extension anteroposterior (AP) views * Prior surgery on the index meniscus * Concomitant surgery such as ligament surgery or cartilage repair or restoration * Infection * Prior cortisone/viscosupplementation/ (platelet rich plasma) PRP injection within 6 weeks

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Osteoarthritis post-meniscectomy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Rush University Medical Center

    Chicago, Illinois, 60612, United States